Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.
Masoud Nouri-VaskehNiusha KalamiRamin ZandZahra SoroureddinMojtaba VarshochiKhalil AnsarinHaleh RezaeeAli TaghizadiehArmin SadeghiMasoud Ahangari MalekiAzam EsmailnajadParviz SalehMehdi HaghdoostMehdi MalekiAkbar SharifiPublished in: International journal of clinical practice (2021)
There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.
Keyphrases
- coronavirus disease
- sars cov
- clinical trial
- blood pressure
- open label
- hypertensive patients
- angiotensin ii
- double blind
- study protocol
- respiratory syndrome coronavirus
- intensive care unit
- randomized controlled trial
- phase ii
- type diabetes
- skeletal muscle
- emergency department
- adipose tissue
- placebo controlled
- adverse drug
- acute care